Anionic Polymer Compositions Blocking Aβ-Oligomer–PrPC Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for amyloid-related disorders, such as Alzheimer's disease, are inadequate, and there is a need for more potent inhibitors of the binding between amyloid-β oligomers and the cellular prion protein, which is crucial for neurodegeneration.
Innovation Solution
Anionic polymers, such as dextran sulfate sodium and pentosan polysulfate, are developed to inhibit the binding of Aβ-oligomer to the cellular prion protein, blocking this interaction and preventing neurodegeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic options are used for amyloid-related disorders, then treatment is provided, but the treatment is inadequate and lacks sufficient efficacy
Solution Approach 1:
The patent employs anionic polymers as intermediary substances that mediate between the Aβ-oligomers and PrPC by binding to the oligomers and preventing their interaction with the cellular prion protein receptor. This intermediary mechanism blocks the neurodegenerative pathway without requiring direct modification of the receptor or oligomer structure, thereby providing effective treatment with existing therapeutic approaches.
2Object-affected harmful factors
If the binding between Aβ-oligomer and cellular prion protein is not inhibited, then the natural pathway proceeds, but neurodegeneration occurs
Solution Approach 1:
The patent extracts or removes the harmful binding interaction between Aβ-oligomers and PrPC by introducing anionic polymers that selectively bind to the oligomers. This extraction of the pathological interaction prevents the downstream neurodegenerative effects while leaving the natural biological systems intact, thereby preventing harm without adding unnecessary complexity to the biological system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These polymers effectively block the Aβ-oligomer/PrPC interaction, showing potential in treating and preventing various amyloid-related disorders by restoring synaptic plasticity and improving memory function in animal models.
Implementation Method 1
Anionic polymers, such as dextran sulfate sodium and pentosan polysulfate, are developed to inhibit the binding of Aβ-oligomer to the cellular prion protein
Data Source
AI summary
The disclosure provides polymeric compounds that inhibit binding of an amyloid-β-oligomer to cellular prion protein, methods for identifying such compounds, and their therapeutic use. In particular, the present disclosure provides a collection of anionic polymers and methods of using these compounds to treat amyloid-related disorders, e.g., Alzheimer's disease.